SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online ...

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Myriad continues to position itself as a leader in genetic testing and precision medicine, aiming to improve patient care and reduce healthcare costs. Myriad Genetics demonstrated operational ...

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower health care costs. For more information, visit Myriad.com.

NDAQ:MYGN) Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces ...

Myriad develops and offers genetic tests that help assess the risk of developing disease ... genetic insights can significantly improve patient care and lower healthcare costs. For more information, ...